Alveo Technologies Announces Partner Program and Portal, New Enablement Software Suite.
Advancing the impact of molecular testing & diagnostics
Our Mission
To enable earlier detection of pathogens at the point of need

Our Vision
Universally accessible molecular detection platform providing industries, communities, and individuals with the tools needed to detect and diagnose earlier, improving outcomes for all

What We Do
At Alveo we understand the importance of access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic molecular diagnostic platform, be.well™, can be adapted to detect a wide range of diseases, bacteria, and other pathogens that threaten public health, across all modalities. We believe increased access to real-time test results will transform the way individuals, healthcare providers and public health professionals identify and manage infectious diseases.

Know Sooner, Act Faster™

Who We Are
We are team-oriented scientists, innovators, data geeks, and entrepreneurs who share a passion for making a positive impact on humanity. We believe that every problem has a clear solution—when you apply the right knowledge and are open to different perspectives. We are proud to be Alveo. We’re dedicated to tackling challenges and improving lives.

Leadership

Shaun Holt
Shaun Holt headshot

Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.
Erik Tyrrell-Knott, JD
Erik Tyrrell-Knott headshot


As Alveo’s Chief Business and Strategy Officer, Erik Tyrrell-Knott leads business and market development, sales, partnering, and product management efforts, driving the Company’s commercial, partnership, and go-to-market strategies. With more than 20 years of experience in strategic business development for medical device and diagnostic companies ranging from start-ups to mature global corporations, Erik most recently served as Vice President of Business Development at Atonarp, Inc., and previously as Head of Business Development for Thermo Fisher Scientific, and previously as Senior Vice President of Business Development and Product Management at Mesa Biotech prior to its acquisition by Thermo Fisher.

Slava Elagin, PhD, MBA
Slava Elagin headshot

Dr. Slava Elagin brings to Alveo more than 20 years of experience in the in vitro diagnostics and medical devices industry. Previously, Slava held senior executive operations and research and development positions with publicly traded and private companies including MiraVista Diagnostics, Meridian Biosciences, EraGen Biosciences, and Third Wave Technologies. He has led 15 molecular diagnostic product development projects from product concept through U.S. Food & Drug Administration clearances and commercialization and is the author on 12 U.S. patents and three global patents for molecular assays and diagnostics.
Ron Keith
Ron Keith headshot

Ron Keith is a career engineering, manufacturing, and supply chain executive, with over 25 years of experience, and currently serves Alveo Technologies as its Chief Operating Officer. He is the founder and Executive Director of Supply Chain Resources Group, which provides manufacturing and supply chain services in six countries to the world’s leading tech product companies and most promising start-ups, and has consulted on product operations, manufacturing, strategy, and supply chain in 22 different countries for more than 100 companies, including a dozen global Fortune 500 companies.
Kevin Gunning
Kevin Gunning headshot


Kevin Gunning oversees Alveo’s Quality Management System and holds more than 25 years of experience working in the medical device, pharmaceutical, biotechnology, and clinical laboratory industries.

Kevin has successfully developed, implemented, and managed quality systems for a number of organizations, ranging from fledgling start-ups to established global corporations. He holds a bachelor’s degree in biological sciences from State University of New York at Buffalo and is an ASQ-certified Quality Auditor.

Lisa Charter
Lisa Charter headshot


Lisa Charter serves as Vice President of Regulatory Affairs at Alveo Technologies, where she brings more than 20 years of experience in regulatory affairs, quality assurance, and research and development in the areas of therapeutic drug monitoring, toxicology, anatomical pathology, hematology, allergy diagnostics, and direct-to-consumer genetics. A veteran medical device professional, Lisa joined Alveo from Atonarp, where she served in a similar capacity. Prior to Atonarp, Lisa led regulatory efforts at 23andMe to secure several first of their kind de novo authorizations and 510(k) clearances for direct-to-consumer genetic tests. Before 23andMe, Lisa held similar roles at Hitachi Chemical Diagnostics and ThermoFisher Scientific.

Helen Belcastro
Helen Belcastro headshot


Helen Belcastro brings over 20 years of experience in cross-functional program and project management in the medical device and biotechnology arenas to her role as Vice President, Portfolio Planning and Program Management at Alveo Technologies. Previously, she applied her program management leadership to the digital transformation of molecular diagnostics at Atonarp, helping to improve clinical outcomes and enhance the patient experience. Prior to Atonarp, Helen built her extensive experience managing complex product development projects at all stages from concept through product release through her work at companies including ViewRay, Inc., VytronUS, Intuitive Surgical, Novartis Vaccines and Diagnostics, and Boston Scientific.

Angie Aquino-Sales
Angie Aquino-Sales headshot


Angie Aquino-Sales serves as Senior Director of People & Culture at Alveo Technologies, where she is focused on human resources strategic planning and organizational design, building HR functions, and designing talent programs for leader and employee development.

Prior to joining Alveo, Angie served at Prologis as a Senior Human Resources Business Partner, at OptiScan Biomedical as Head of HR, and at Tripping.com as Director of HR. Angie has experience working in start-ups and small businesses in a variety of industries. She has held related roles in large organizations including Kaiser Permanente, Blue Shield of California, and McKesson.

Mary K. McFillin
Mary K. McFillin headshot


Mary McFillin is a senior global product marketing manager with extensive experience in the point-of-care diagnostics industry, leading strategy, development, and support of in vitro diagnostics medical devices throughout the product life cycle. As a senior product management executive, Mary leads Alveo’s strategic marketing and target market development. She joins Alveo from Thermo Fisher Scientific, Rapid Diagnostic Solutions, where she served as Senior Manager of Product Management. Previously, she held similar positions for Abbott Laboratories and Alere, Inc.

Board of Directors

Shaun Holt
Shaun Holt headshot


Shaun Holt serves as Chairman of the Board and Chief Executive Officer of Alveo Technologies. Previously, Shaun served as Chief Operating Officer of Atonarp, Inc., a Celesta Capital-backed optical- and mass-spectrometry instrumentation company. Prior to Atonarp, as Chief Financial Officer for Berkeley Lights, Inc., Shaun led the digital cell biology company through its $205 million initial public offering. In addition, Shaun held numerous finance leadership positions during his seven-year tenure at Illumina throughout its exponential growth phase. He brings more than 20 years of operational and financial leadership experience across various technology and life sciences companies from start-ups to large-capitalization companies. Shaun is an advisor to Celesta Capital and serves on the Board of Directors of Prellis Biologics.

Michael Marks
Michael Marks headshot


For 40 years, Michael Marks has successfully led and transformed technology companies. He is a founding managing partner at Celesta Capital, where he co-leads the firm. From 2007 to 2019, he was a founding partner at Riverwood Capital Management, a private equity fund specializing in rapidly growing private companies in North America and emerging markets. He was a partner and senior advisor at Kohlberg Kravis Roberts & Co (KKR) in 2006 and 2007. Before KKR, he spent 13 years as Chairman and CEO of Flextronics International Ltd and built the company into one of the largest technology companies in the world.

Who Supports Alveo’s Vision

Alveo’s investors that share and support our vision.